Ocular solutions

Details Ocular solutions Ocular solutions

2006-08-08

2006-08-08

Sheikh, Humera N. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

C424S422000, C424S423000, C424S427000, C424S428000

Reexamination Certificate

active

07087237

ABSTRACT:
Containing at least one macrolide antibiotic and/or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions.

REFERENCES:
patent: 4079038 (1978-03-01), Choi et al.
patent: 4093709 (1978-06-01), Choi et al.
patent: 4131648 (1978-12-01), Choi et al.
patent: 4138344 (1979-02-01), Choi et al.
patent: 4180646 (1979-12-01), Choi et al.
patent: 4304767 (1981-12-01), Heller et al.
patent: 4946931 (1990-08-01), Heller et al.
patent: 5294604 (1994-03-01), Nussenblatt et al.
patent: 5387589 (1995-02-01), Kulkarni
patent: 5411952 (1995-05-01), Kaswan
patent: 5411962 (1995-05-01), Hanson et al.
patent: 5457182 (1995-10-01), Wiederrecht et al.
patent: 5770607 (1998-06-01), Honbo et al.
patent: 5773019 (1998-06-01), Ashton et al.
patent: 5952371 (1999-09-01), Baker et al.
patent: 5968543 (1999-10-01), Heller et al.
patent: 6004565 (1999-12-01), Chiba
patent: 6179817 (2001-01-01), Zhong
patent: 6238799 (2001-05-01), Opolski
patent: 6239113 (2001-05-01), Dawson et al.
patent: 6258856 (2001-07-01), Chamberlain et al.
patent: 6306422 (2001-10-01), Batich et al.
patent: 6331313 (2001-12-01), Wong et al.
patent: 6350442 (2002-02-01), Garst
patent: 6436906 (2002-08-01), Or et al.
patent: 6440942 (2002-08-01), Or et al.
patent: 6462026 (2002-10-01), Or et al.
patent: 6462071 (2002-10-01), Castillejos
patent: 6482799 (2002-11-01), Tuse et al.
patent: 6489335 (2002-12-01), Peyman
patent: 6534693 (2003-03-01), Fischell et al.
patent: 6596296 (2003-07-01), Nelson et al.
patent: 6613355 (2003-09-01), Ng et al.
patent: 6617345 (2003-09-01), Gregory et al.
patent: 6667371 (2003-12-01), Ng et al.
patent: 6670398 (2003-12-01), Edwards et al.
patent: 6673807 (2004-01-01), Sakai et al.
patent: 6713081 (2004-03-01), Robinson et al.
patent: 6864232 (2005-03-01), Ueno
patent: 6872383 (2005-03-01), Ueno
patent: 2002/0015957 (2002-02-01), Hageman et al.
patent: 2002/0187998 (2002-12-01), Ueno
patent: 2003/0044452 (2003-03-01), Ueno
patent: 2003/0069232 (2003-04-01), Chiou
patent: 2003/0130301 (2003-07-01), Ueno
patent: 2004/0092435 (2004-05-01), Peyman
patent: 2004/0198763 (2004-10-01), Ueno
patent: 2005/0025810 (2005-02-01), Peyman
patent: 2005/0063996 (2005-03-01), Peyman
patent: 2005/0063997 (2005-03-01), Peyman
patent: 2005/0064010 (2005-03-01), Cooper et al.
patent: 2005/0070468 (2005-03-01), Ueno
patent: 17386/88 (1991-03-01), None
patent: 20350/92 (1993-01-01), None
patent: 1333018 (2002-01-01), None
patent: 1340358 (2002-03-01), None
patent: 1456350 (2003-11-01), None
patent: 19810655 (1999-09-01), None
patent: 0 532 862 (1993-03-01), None
patent: 1074255 (2001-02-01), None
patent: 1142566 (2001-10-01), None
patent: 07010752 (1995-01-01), None
patent: 1997030966 (1997-02-01), None
patent: 09315954 (1997-12-01), None
patent: 10-218787 (1998-08-01), None
patent: 2001-064198 (2001-03-01), None
patent: WO 89/01772 (1989-03-01), None
patent: WO 99/22722 (1999-05-01), None
patent: WO 99/34830 (1999-07-01), None
patent: WO 99/42104 (1999-08-01), None
patent: WO 00/66122 (2000-11-01), None
patent: WO 02/24234 (2002-03-01), None
patent: WO 02/085928 (2002-10-01), None
patent: WO 03/017990 (2003-03-01), None
patent: WO 03/051385 (2003-06-01), None
patent: WO 2004/014373 (2004-02-01), None
patent: WO2004/027027 (2004-04-01), None
patent: WO 2004/043480 (2004-05-01), None
patent: WO 2004/096261 (2004-11-01), None
patent: WO 2005/011813 (2005-02-01), None
patent: WO2005/027906 (2005-03-01), None
patent: WO 2005/030205 (2005-04-01), None
PCT,International Search Report, PCT/US2004/030186, mailed Feb. 8, 2005, received Feb. 14, 2005, 7 pg.
D. Aron-Rosa,Pulsed Nd:YAG lasers in ophthalmology, Nd:YAG Laser Applications, pp. 34-48 (1986).
Steven H. Dewey, MD,2003 PCO Update: Part 1—How the square-edged IOL prevenst posterior capsular opacification, Cataract & Refractive Surgery Today, Sep. 2003, pp. 20-22.
Goodman & Gilman,The Pharmacological Basis of Therapeutics, 8th Ed., Pergamon Press, New York, 1990, pp. 1024-1033.
Peyman, et al.,Vitreoretinal Surgical Techniques, Martin Dunitz, London, 2001, Chapter 45, pp. 521-531.
Peyman,U.S. Patent Application Publication, Treatment of Ocular Disease, U.S. Appl. No. 10/247,220, filed Sep. 19, 2002, published Jan. 23, 2003.
Gholam Peyman, MD,Pupillary Membranes: Nd:YAG Capsulotomy, Intravitreal Surgery, Norwalk CT, Appleton & Lange, 1994, pp. 253-257.
Wise,Handbook of Pharmaceutical Controlled Release Technology, Marcel Dekker, New York, 2000.
Schonfield and Kirst,Macrolide Antibiotics, Birkhausen, Basil, Switzerland, 2002, pp. 1-36.
Algvere et al,Long-term outcome of RPE allografts in non-Immunosuppressed patients with AMD, European J of Ophthalmology (1999), 9(3):217-230.
Anderson et al.,A Role for Local Inflammation in the Formation of Drusen in the Aging Eye, American Journal of Ophthalmology, vol. 134, No. 3, Sep. 2002, pp. 411-431.
Apel et al.,A subconjunctival degradable implant for cyclsoprine delivery in corneal transplant therapy, Curr. Eye Res. 14:659-667, 1995.
Aramant et al,Retinal transplantation, Science & Medicines (2000), 7:20-29.
Carmo et al,Effect of cyclosporin A on the blood-retinal barrier permeability in streptozotocin-induced diabetes, Mediators of Inflammation (2000), 9(5):243-248.
Cicciarell et al,Pharmacokinetics of subconjunctivally administered cylcosporine A. Local delivery prior to chemotherapy for retinoblastoma, IOVS (Mar. 15, 2001), 42(4):S332.
Costantini LC, et al.,Immuophilin Ligands and GDNF Enhance Neurite Branching or Elongation from Developing Dopamine Neurons in Culture, Experimental Neurology 164,60-60 (2000).
Das et al,The transplantation of human fetal neuroretinal cells in advanced retinitis pigmentosa patients: Results of a long-term safety study, Experimental Neurology (1999), 157:58-68.
Del Cerro et al,Histologic correlation of human neural retinal transplantation, Invest. Ophthalmology & Visual Science (2000), 41(10):3142-3148.
Donnenfeld et al.,Cyclosporine provides effective treatment for dry eye, Therapeutic Updates in Ophthalmology, Special Issue, Jul. 1999, pp. 1-3.
Enyedi et al,Pharmacokinetics and toxicity of an intravitreal device providing sustained release of cyclosporine(CsA)and dexamethasone(DEX), Invest. Ophthalmology and Visual Science, vol. 35, No. 4, 1994, p. 1906, and Annual Meeting of the Association for Research in Vision and Ophthalmology, Sarasota, FL, USA, May 1-6, 1994, abstract.
Enyedi et al,An intravitreal device providin sustained release of cyclsporine and dexamethasone, Curr. Eye Res. May 1996, vol. 15, No. 5, pp. 549-557.
Garweg et al,Therapy of Goldmann-Favre's Vitreo-Retinal Degeneration with Cyclosporin A and Bromocriptine, Klinische Monatsblatter fur Augenheilkunde, vol., 199, No. 3, Sep. 1991, pp. 199-205.
Gilbard,EW Interview: Electrolyte balance is key to dry-eye product's success, EyeWorld, Feb. 2000, pp. 20ff.
Grisolano et al.,Retinal Toxicity Study of Intravitreal Cyclosporin, Opthalmic Surgery, Mar. 1986, 17:155-156.
Jiang et al,Corneal electroretinographic function rescued by normal retinal pigment epithelial grafts in retinal degenerative Royal College of Surgeons rats, Invest. Ophthalmology & Visual Science (1994), 35(13):4300-4308.
Karacorlu et al.,Lack of toxicity of Intravitreally administered interferon Alpha-2a, Ophthalmic Surger (1999), 23:833-35.
Keep et al.,Introduction: Immunosuppressant

Affiliated with

Also associated with

Rating

Ocular solutions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ocular solutions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ocular solutions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3696315